Meta AnalysisID 3675
硝苯地平治疗原发性痛经 [Cochrane方案]
CRD42018086159
To assess the effectiveness and safety of nifedipine for primary dysmenorrhoea.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3675
- Evidence Id
- 12233
- Core Evidence Id
- 12233
- Source Meta Analysis Id
- 3634
- Herb2 Meta Analysis Id
- HBMA003634
- Crd Id
- CRD42018086159
- Title
- Nifedipine for primary dysmenorrhoea [Cochrane protocol]
- Review Question
- To assess the effectiveness and safety of nifedipine for primary dysmenorrhoea.
- Study Type Included
- Published and unpublished randomised controlled trials (RCTs) will be eligible for inclusion. We will exclude non- randomised studies (e.g. studies with evidence of inadequate sequence generation such as alternate days, patient numbers) because they are associated with a high risk of bias. Cross-over trials will be included, because cross-over is a valid design in this context.
- Condition Being Studied
- The Cochrane Gynaecology and Fertility Group
- Participant
- Women with primary dysmenorrhoea will be eligible for inclusion. Primary dysmenorrhoea will be defined as painful uterine cramps associated with menstrual periods in the absence of known pelvic pathology.
- Animal
- Human Disease Modelled
- Intervention
- Trials comparing nifedipine with any other pharmacologic intervention or placebo will be eligible for inclusion. Trials comparing the addition of nifedipine to other pharmacological agents will also be included; for example 'drug x plus nifedipine versus drug X alone'. Nifedipine may be administered by any route. Nifedipine has not been included in other published Cochrane Reviews regarding dysmenorrhoea as a comparator. For technical reasons the intervention and comparators fields for Cochrane protocols are identical and each may include information on both interventions and comparators
- Comparator Control
- Trials comparing nifedipine with any other pharmacologic intervention or placebo will be eligible for inclusion. Trials comparing the addition of nifedipine to other pharmacological agents will also be included; for example 'drug x plus nifedipine versus drug X alone'. Nifedipine may be administered by any route. Nifedipine has not been included in other published Cochrane Reviews regarding dysmenorrhoea as a comparator. For technical reasons the intervention and comparators fields for Cochrane protocols are identical and each may include information on both interventions and comparators
- Main Outcome
- 1. Pain Eligible measures of pain will include: 0 to 10 numeric pain rating scale (preferred); visual analogue scale; binary pain measures (i.e. yes/no); and other measures of pain as reported in the included studies.</ul> 2. Health-related quality of life (QoL) using a validated tool such as SF-36 (preferred measure).
- Outcome Measure
- Additional Outcome
- 1. Adverse effects (including the following examples): any adverse effect; headache; facial flushing; dizziness/faintness/symptomatic hypotension; and palpitations/symptomatic tachycardia.</ul> 2. Satisfaction rate (as defined by trial authors). 3. Requirement for additional medication. This will be measured by yes/no answer, including different types and doses of other medications. We anticipate that studies may report outcomes at multiple time points. We will use data from the longest period of follow up for our primary and secondary outcomes.
- Study Method
- Intervention, Systematic review
- Keyword
- Dysmenorrhea; Female; Humans; Nifedipine; Pelvis
- Contact
- Rachel A Earl [email protected]
- Organisational Affiliation
- The Cochrane Collaboration http://www.cochrane.org/
- Funding Source
- No formal sources of support No formal sources of support
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012912/abstract
- Review Type
- Language
- English
- Country
- Australia
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2018-01-15
- Anticipated Start Date
- 2017-12-15
- Anticipated Completion Date
- 2018-12-15
- Title Cn
- 硝苯地平治疗原发性痛经 [Cochrane方案]
- Title En
- Nifedipine for primary dysmenorrhoea [Cochrane protocol]
- Bilingual Status
- complete